Latest News on ZBH

Financial News Based On Company


Advertisement
Advertisement

Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Mentari Therapeutics (MTRI) and Lexeo Therapeutics, Inc. (LXEO)

https://www.theglobeandmail.com/investing/markets/stocks/ISRG/pressreleases/8911660/analysts-offer-insights-on-healthcare-companies-intuitive-surgical-isrg-mentari-therapeutics-mtri-and-lexeo-therapeutics-inc-lxeo/
Three analysts have issued bullish sentiments on several healthcare companies. Intuitive Surgical (ISRG) received a Buy rating with a $518 price target from BMO Capital and a $500 target from Bank of America Securities. Mentari Therapeutics (MTRI) was also rated Buy by Wedbush and Stifel Nicolaus, with price targets of $33 and $30 respectively. Lexeo Therapeutics, Inc. (LXEO) maintained a Buy rating from RBC Capital with a $20 price target and Cantor Fitzgerald with a $23 price target.

Sintx Technologies, Inc. (SINT) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/SINT/
Sintx Technologies, Inc. (SINT) stock closed at $1.2050, down 2.82%, with a market cap of $9.108 million. The company, which specializes in silicon nitride biomaterials for medical and other applications, has seen significant negative returns over the past year, with a 1-year return of -63.48% and a 5-year return of -99.99%. Analysts maintain a "Buy" rating with a target price of $12.50.

Price to sales forward of Zimmer Biomet Holdings, Inc. – HAM:ZIM

https://www.tradingview.com/symbols/HAM-ZIM/financials-statistics-and-ratios/price-sales-fwd/
This article provides the forward price-to-sales ratio for Zimmer Biomet Holdings, Inc. (HAM:ZIM). It's a brief financial data point from TradingView, focusing on the company's valuation metric without further analysis. The content is primarily a data presentation rather than an in-depth article.

United Airlines Had a “Widespread System Outage,” 3 Days After the FAA Ground Stop

https://247wallst.com/investing/2026/11/17/united-airlines-had-a-widespread-system-outage-3-days-after-the-faa-ground-stop/
United Airlines experienced a "widespread system outage" on November 16, 2026, causing over 90 minutes of departure delays and affecting hundreds of flights, just days after a nationwide FAA ground stop. This incident challenges CEO Scott Kirby's claims about United's technological advantage, especially given a similar Unimatic outage in August 2025. While the stock's immediate reaction was minimal, the repeated tech issues could impact United's reliability perception, particularly leading into the busy Thanksgiving travel period.

Zimmer Biomet upgraded by Wells Fargo with a new price target

https://www.quantisnow.com/insight/zimmer-biomet-upgraded-by-wells-fargo-with-a-new-price-6795686
Wells Fargo has upgraded Zimmer Biomet (ZBH) from Equal Weight to Overweight, setting a new price target of $123.00. This upgrade follows a period where the stock has shown varied performance after previous headlines, with a median move of 1.3% in either direction in the sessions following announcements.
Advertisement

This Medtronic Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

https://www.benzinga.com/analyst-stock-ratings/upgrades/26/11/63337775/this-medtronic-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday-2
Top Wall Street analysts have updated their ratings for several companies, with Medtronic plc among them. Piper Sandler analyst Matt O’Brien upgraded Medtronic from Neutral to Overweight, raising its price target. Other companies receiving upgrades include United Natural Foods, Zimmer Biomet Holdings, Nucor Corporation, and Praxis Precision Medicines.

Zimmer Biomet upgraded by Wells Fargo with a new price target

https://quantisnow.com/insight/zimmer-biomet-upgraded-by-wells-fargo-with-a-new-price-6795686
Wells Fargo has upgraded Zimmer Biomet (ZBH) from Equal Weight to Overweight, setting a new price target of $123.00. This upgrade, reported by Quantisnow, highlights a positive shift in analyst sentiment towards the medical technology company. Historically, ZBH has shown varied reactions to headlines, with a median move of 1.3% after previous announcements.

Guggenheim initiates Lycia Therapeutics stock with buy rating

https://www.investing.com/news/analyst-ratings/guggenheim-initiates-lycia-therapeutics-stock-with-buy-rating-93CH-5032330
Guggenheim initiated coverage on Lycia Therapeutics (NASDAQ:LYCA) with a buy rating and a price target of $75.00, citing the potential of its cataLYTAC platform and lead asset LCA-0061 for immune-mediated diseases and food allergies. The firm also highlighted LCA-0321 for Graves' disease, noting the company's strong liquidity despite being unprofitable. Other analysts from Evercore ISI, Jefferies, and TD Cowen have also initiated coverage with positive ratings.

Wells Fargo upgrades Zimmer Biomet Holdings to Overweight from Equal-Weight, raises price target to $123

https://www.tradingview.com/news/tradingview:8977ba9940b28:0-wells-fargo-upgrades-zimmer-biomet-holdings-to-overweight-from-equal-weight-raises-price-target-to-123/
Wells Fargo has upgraded Zimmer Biomet Holdings (ZBH) from Equal-Weight to Overweight and increased its price target to $123 from $113, implying a 21.3% upside from the recent closing price. This move reflects a more positive outlook on the company, despite other analysts maintaining various ratings and price targets ranging from $101 to $140.

Hercules Capital tops $4B in annual commitments for first time

https://www.streetinsider.com/Corporate+News/Hercules+Capital+tops+%244B+in+annual+commitments+for+first+time/27358847.html
Hercules Capital, Inc. (NYSE: HTGC) has achieved a new record, surpassing $4.0 billion in total debt and equity commitments for the first time in 2026, exceeding its prior single-year high of $3.92 billion. This milestone includes commitments made by Hercules Capital and its private funds, demonstrating the continued growth of its venture and growth stage lending platform. The company, a specialty finance firm, focuses on senior secured venture growth loans to technology and life sciences companies.
Advertisement

Ares Management, Claritev Corp director, buys $390,403 in ctev stock

https://www.investing.com/news/insider-trading-news/ares-management-claritev-corp-director-buys-390403-in-ctev-stock-93CH-5031373
Ares Management LLC, a director and 10% owner of Claritev Corp (NASDAQ:CTEV), recently acquired 13,587 shares of Class A Common Stock for $390,403, despite the stock currently trading below the purchase price but having surged 80% in the last six months. This transaction increases Ares Management's indirect beneficial ownership to over 2 million shares, held through various Ares entities. InvestingPro analysis suggests Claritev is overvalued, yet the company reported strong Q3 2026 revenue and an improved full-year outlook, leading Piper Sandler to raise its price target.

BMO Capital maintains Zimmer Biomet Holdings at Market Perform, lowers price target to $101 from $102

https://www.tradingview.com/news/tradingview:06bdb3956baf2:0-bmo-capital-maintains-zimmer-biomet-holdings-at-market-perform-lowers-price-target-to-101-from-102/
BMO Capital has reiterated its "Market Perform" rating for Zimmer Biomet Holdings, while slightly reducing its price target from $102 to $101, representing a 1.0% decrease. This new price target suggests a 2.1% downside from the stock's closing price on November 13th. Other recent analyst actions on Zimmer Biomet Holdings over the past 30 days have set price targets ranging from $115 to $140.

BMO cuts Zimmer Biomet stock price target on debt refinancing costs

https://www.investing.com/news/analyst-ratings/bmo-cuts-zimmer-biomet-stock-price-target-on-debt-refinancing-costs-93CH-5030193
BMO Capital has reduced its price target for Zimmer Biomet (NYSE:ZBH) shares to $101 from $102, citing an estimated $17 million in incremental annual interest expense from the company's recent dual-currency debt offering. This refinancing is expected to result in a 7-cent full-year headwind to earnings per share. Despite the cut, the stock trades above the new target, and InvestingPro analysis suggests it remains undervalued.

Stifel maintains Zimmer Biomet Holdings at Buy, raises price target to $140 from $125

https://www.tradingview.com/news/tradingview:9856ebe48bc0f:0-stifel-maintains-zimmer-biomet-holdings-at-buy-raises-price-target-to-140-from-125/
Stifel has reaffirmed its "Buy" rating for Zimmer Biomet Holdings and increased its price target to $140 from $125, representing a 12.0% increase. This new target implies a 35.6% upside from the stock's closing price of $103.21 on November 13. This analyst action follows several others in early November, with price targets ranging from $115 to $130 among the five most recent notes.

Weekly Recap: Notes Issued and Q3 Sales Growth Guidance Raised

https://www.tradingview.com/news/tradingview:87d1e256adb85:0-weekly-recap-notes-issued-and-q3-sales-growth-guidance-raised/
Zimmer Biomet Holdings, Inc. (ZBH) issued €500 million and $500 million in notes to fund corporate needs and potentially repay existing debt. The company also reported a 3.1% year-over-year increase in third-quarter 2026 sales to $2.063 billion and subsequently raised its full-year revenue growth guidance. Barclays maintained its Equal-Weight rating on ZBH and increased its price target from $100 to $115.
Advertisement

Alberta Investment Management Corp Purchases 252,106 Shares of Zimmer Biomet Holdings, Inc. $ZBH

https://www.marketbeat.com/instant-alerts/filing-alberta-investment-management-corp-purchases-252106-shares-of-zimmer-biomet-holdings-inc-zbh-2026-11-16/
Alberta Investment Management Corp significantly increased its stake in Zimmer Biomet Holdings, Inc. by 84.6% during the third quarter, acquiring an additional 252,106 shares. This brings their total holdings to 550,000 shares, valued at approximately $48.9 million. The company recently exceeded quarterly earnings and revenue expectations and maintains a consensus "Hold" rating from analysts with an average price target of $112.74.

Form 4 Zimmer Biomet Holdings Inc: Kevin R. Thornal (Grp Pres-Global Business) For: 11 September

https://ng.investing.com/news/stock-market-news/form-4-zimmer-biomet-holdings-inc-kevin-r-thornal-grp-presglobal-business-for-11-september-93CH-2808743
This article reports on a Form 4 filing for Zimmer Biomet Holdings Inc, specifically detailing an action by Kevin R. Thornal, Group President of Global Business, on September 11. The filing provides transparency regarding insider transactions at the company.

Form 4 Zimmer Biomet Holdings Inc: Kevin R. Thornal (Grp Pres-Global Business) For: 11 September By Investing.com

https://in.investing.com/news/stock-market-news/form-4-zimmer-biomet-holdings-inc-kevin-r-thornal-grp-presglobal-business-for-11-september-93CH-5705524
This article reports on a Form 4 filing for Zimmer Biomet Holdings Inc., detailing an insider transaction by Kevin R. Thornal, Group President of Global Business, on September 11. The brief piece indicates a filing related to insider trading activities within the company, often a point of interest for investors tracking executive stock movements.

Form 4 Zimmer Biomet Holdings Inc: Kevin R. Thornal (Grp Pres-Global Business) For: 11 September

https://au.investing.com/news/stock-market-news/form-4-zimmer-biomet-holdings-inc-kevin-r-thornal-grp-presglobal-business-for-11-september-93CH-4771960
This article reports on a Form 4 filing for Zimmer Biomet Holdings Inc, specifically detailing an insider transaction involving Kevin R. Thornal, the Group President of Global Business, on September 11th. The publication, from Investing.com, indicates the filing was made on November 16, 2026. This type of filing provides transparency regarding changes in ownership by company insiders.

Form 4 Zimmer Biomet Holdings Inc: Kevin R. Thornal (Grp Pres-Global Business) For: 11 September

https://ca.investing.com/news/stock-market-news/form-4-zimmer-biomet-holdings-inc-kevin-r-thornal-grp-presglobal-business-for-11-september-93CH-4959434
This article reports on a Form 4 filing for Zimmer Biomet Holdings Inc, specifically detailing the activities of Kevin R. Thornal, Group President-Global Business, for September 11. The article itself is a brief announcement without further details on the nature of the transaction.
Advertisement

Wall Street Zen Upgrades Zimmer Biomet (NYSE:ZBH) to "Buy"

https://www.marketbeat.com/instant-alerts/analyst-wall-street-zen-upgrades-zimmer-biomet-nyse-zbh-to-buy-2026-11-14/
Wall Street Zen has upgraded Zimmer Biomet (NYSE:ZBH) from a "hold" to a "buy" rating. Despite this upgrade, the broader analyst consensus for ZBH remains "hold" with an average price target of $112.74. The company recently exceeded quarterly earnings and revenue estimates, though insider sales have also been reported.

iRhythm Technologies CEO Joins Align Technology’s Board of Directors

https://www.mpo-mag.com/breaking-news/irhythm-technologies-ceo-joins-align-technologys-board-of-directors/
Align Technology has appointed Quentin Blackford, President and CEO of iRhythm Technologies, to its Board of Directors, replacing the retiring Andrea Saia. Blackford brings extensive experience in global healthcare, medical technology, and digital innovation from his roles at iRhythm Technologies, Dexcom, NuVasive Inc., and Zimmer Holdings. Align Technology credits Saia for her significant contributions to the company's growth and strategic oversight during her 13-year tenure.

What Pacira BioSciences Doubters Got Wrong

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/what-pacira-biosciences-doubters-got-wrong-1
Pacira BioSciences saw a 49.2% return, including dividends, from the start of the year, despite skepticism. Bullish arguments in 2025 focused on CMS policy shifts, ambulatory surgery growth, and a Johnson & Johnson MedTech partnership, while bears highlighted reliance on EXPAREL and generic threats. The recent US$36.50 per share cash tender from Viatris, coupled with improved profitability on flatter revenue, suggests the optimists were more accurate.

Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates

https://www.globenewswire.com/news-release/2026/11/10/3400189/21634/en/stereotaxis-reports-2026-third-quarter-financial-results-business-updates.html
Stereotaxis (NYSE: STXS) reported a 20% increase in third-quarter 2026 revenue to $8.9 million, driven by strong system sales and growth in robotically-navigated catheters. The company is focusing on transitioning to more accessible and scalable systems and developing disposable interventional catheters for recurring revenue. Stereotaxis also announced a convertible note financing of up to $24 million to bolster its cash balance and support future growth.

Enovis (NYSE:ENOV) Q3 2026: Recon Growth, Guidance Raised

https://kalkinemedia.com/us/stocks/healthcare/enovis-nyseenov-q3-2026-recon-growth-guidance-raised
Enovis (NYSE:ENOV) reported strong Q3 2026 results, with sales growth on both reported and organic bases, driven by significant market share gains in its Reconstructive segment. The company also raised its full-year guidance for adjusted EBITDA and adjusted EPS, reflecting confidence in margin improvement and successful execution of its innovation-led strategy. This performance highlights Enovis's ability to capitalize on steady demand from an aging population and advancements in orthopedic medical technology.
Advertisement

Zimmer Biomet Introduces Surgeon-Guided Autonomy for Intelligent Orthopedic Surgery

https://www.digitalhealthnews.com/zimmer-biomet-introduces-surgeon-guided-autonomy-for-intelligent-orthopedic-surgery
Zimmer Biomet Holdings, Inc. has introduced "Surgeon-Guided Autonomy," a new technology designed to integrate surgical planning, execution, and patient recovery through intelligent systems while maintaining surgeon control over clinical decisions. This framework, built around "Predict, Perform, Recover," aims to translate surgeon intent into actions, allowing technology to handle cognitive and physical tasks without replacing human judgment. The approach emphasizes understanding surgeon intent, executing defined tasks, maintaining surgeon command, and connecting outcomes with recovery data to inform future treatment plans.

Edwards Lifesciences (NYSE:EW) VP Donald Bobo Jr Sells 48,900 Shares of Stock

https://www.marketbeat.com/instant-alerts/insider-edwards-lifesciences-nyse-ew-vp-donald-bobo-jr-sells-48900-shares-of-stock-2026-11-09/
Edwards Lifesciences VP Donald Bobo Jr. sold 48,900 shares of the company's stock for approximately $5.04 million on November 9, 2026, under a pre-arranged Rule 10b5-1 trading plan. This transaction significantly reduced his holdings by 68.2%, leaving him with 22,798 shares. The company recently reported strong quarterly earnings, beating analyst estimates, and the stock traded up 2.5% following the news.

Form 424B5 Zimmer Biomet Holdings Inc For: 9 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-424b5-zimmer-biomet-holdings-inc-for-9-november-93CH-4944375
This article from Investing.com announces the filing of Form 424B5 by Zimmer Biomet Holdings Inc. on November 9, 2026. The filing is presented without additional commentary or details beyond its identification and publication date. It includes a general financial market overview and trending stock information from Investing.com.

Form 424B5 Zimmer Biomet Holdings Inc For: 9 November By Investing.com

https://in.investing.com/news/stock-market-news/form-424b5-zimmer-biomet-holdings-inc-for-9-november-93CH-5691834
This article from Investing.com announces the filing of Form 424B5 by Zimmer Biomet Holdings Inc. for November 9th. The content is primarily a placeholder for the SEC filing, providing no further details within the article itself but noting the company's stock symbol ZBH. The publication focuses on financial market information.

Form 424B5 Zimmer Biomet Holdings Inc For: 9 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-424b5-zimmer-biomet-holdings-inc-for-9-november-93CH-4969573
This article announces the filing of Form 424B5 for Zimmer Biomet Holdings Inc on November 9, 2026. The brief piece, published by Investing.com, serves as a direct notification of this financial filing, providing minimal additional detail beyond the core announcement. It also lists ZBH with a 2.59% increase.
Advertisement

Stryker stock faces lower 2026 outlook after Q3 earnings miss

https://www.ad-hoc-news.de/boerse/news/corporate-news/stryker-stock-faces-lower-2026-outlook-after-q3-earnings-miss/70482027
Stryker Corp. has lowered its full-year 2026 outlook following a third-quarter performance that fell short of management expectations, despite reporting stronger sales growth. While adjusted operating margin expanded, a goodwill impairment impacted reported earnings. The company now forecasts reduced organic sales growth and adjusted diluted earnings per share, raising execution pressure for investors.

Zimmer Biomet Outlines Manufacturing Changes In Warsaw

https://www.inkfreenews.com/2026/11/09/zimmer-biomet-outlines-manufacturing-changes-in-warsaw/
Zimmer Biomet is restructuring its manufacturing and distribution operations, consolidating production facilities in Warsaw and moving some distribution functions to Indianapolis by the end of 2028. The company also plans to move its corporate headquarters to the West Campus and anticipates that nearly all manufacturing positions in Warsaw will remain in place. These changes are part of a broader cost-reduction program launched in early 2025.

ZBH6565427 Bond Yield and Price — FINRA:ZBH6565427

https://www.tradingview.com/symbols/FINRA-ZBH6565427/
This article provides details on the ZBH6565427 bond issued by Zimmer Biomet Holdings, Inc., including its coupon rate, maturity date, and key identifiers. It also offers information about the issuer's business, geographical segments, and founding history. The bond's profile and risk level information are also mentioned as features available for users.

What Shoulder Innovations (SI) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:2e80c7b6f094b:0-what-shoulder-innovations-si-said-on-its-q3-earnings-call/
Shoulder Innovations (SI) reported a 38% increase in Q3 revenue, reaching $16.2 million, and raised its full-year 2026 revenue outlook to $68 million to $70 million. The growth was driven by new surgeon additions and increased implant usage, despite seasonal pressures. The company also saw an improvement in gross margin and a narrowing of its net and adjusted EBITDA losses, while advancing its product pipeline, including new implant launches and robotic technology development.

Zimmer Biomet details cost of consolidation efforts

https://www.21alivenews.com/2026/11/07/zimmer-biomet-details-cost-consolidation-efforts/
Zimmer Biomet Holdings Inc. expects to incur approximately $60 million in exit costs, primarily severance charges, as it consolidates manufacturing facilities in Indiana, New Jersey, and Switzerland. The company's Manufacturing Network Optimization Plan includes a potential reduction of up to 580 jobs in Winterthur, Switzerland, and the transfer of New Jersey operations to existing Warsaw sites. Zimmer Biomet also plans to relocate its corporate headquarters and donate its former building to Grace College for an Orthopedic Innovation Research Center.
Advertisement

Shoulder Innovations, Inc. (NYSE:SI) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

https://simplywall.st/stocks/us/healthcare/nyse-si/shoulder-innovations/news/shoulder-innovations-inc-nysesi-just-released-its-third-quar
Shoulder Innovations, Inc. (NYSE:SI) reported strong third-quarter results, with revenues of US$16m exceeding estimates by 4.7% and statutory losses smaller than expected at US$0.34 per share. Analysts have maintained their revenue and loss per share forecasts for 2027, projecting US$88.4m in revenue and a loss of US$1.57 per share, with the consensus price target remaining at US$27.00. The company is expected to grow faster than the wider industry, despite a forecasted slowdown in revenue growth compared to historical rates.

Enovis Stock Earnings Beat Spurs New $200 Million Buyback Plan

https://simplywall.st/stocks/us/healthcare/nyse-enov/enovis/news/enovis-stock-earnings-beat-spurs-new-200-million-buyback-pla
Enovis reported strong third-quarter 2026 results, returning to profitability and exceeding sales expectations. The company also announced a new $200 million share repurchase authorization, signaling confidence in its financial health and operational improvements. This move aims to enhance per-share metrics and reshape the company's earnings profile following a period of stock decline.

Learn Why The Bull Case For Envista Holdings Stock Could Change Following Earnings Guidance Raise

https://simplywall.st/stocks/us/healthcare/nyse-nvst/envista-holdings/news/learn-why-the-bull-case-for-envista-holdings-stock-could-cha
Envista Holdings reported strong Q3 2026 results with a swing to profit and raised its full-year adjusted earnings guidance, driven by pricing actions, productivity gains, and growth in digital dental products. This positive performance occurred despite challenges like weaker demand and Volume Based Procurement headwinds in China. The upgraded outlook and margin expansion are expected to reshape the investment narrative for Envista Holdings, shifting focus towards sustained margin gains offsetting ongoing regional pressures.

Edwards Lifesciences Corporation $EW Stock Sold by Boston Trust Walden Corp

https://www.marketbeat.com/instant-alerts/filing-edwards-lifesciences-corporation-ew-stock-sold-by-boston-trust-walden-corp-2026-11-06/
Boston Trust Walden Corp reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 5.3% in the third quarter, selling 13,624 shares while retaining a substantial holding valued at over $21 million. This reduction occurred despite other institutional investors, like Assenagon Asset Management S.A., increasing their positions. Edwards Lifesciences reported strong Q3 earnings, beating analyst estimates with EPS of $0.80 and revenue of $1.72 billion, leading to a "Moderate Buy" consensus rating from analysts with an average price target of $108.88.

A new surgery vision would give technology more work, while surgeons keep control.

https://www.stocktitan.net/news/ZBH/zimmer-biomet-introduces-surgeon-guided-autonomy-a-new-category-in-hj02zhxvzazt.html
Zimmer Biomet is introducing "Surgeon-Guided Autonomy," a new technology category for intelligent orthopedic surgery that aims to shift the burden of cognitive and physical work to intelligent systems while surgeons retain full control and expertise. This vision is built around a "Predict. Perform. Recover." framework, connecting patient-specific planning, autonomous task execution, and recovery analysis in a continuous loop. The company believes this approach will empower surgeons and lead the future of orthopedics by integrating intelligence, robotics, and data throughout the care journey.
Advertisement

Zimmer Biomet launches Surgeon-Guided Autonomy, a new tech category enhancing surgeon control in orthopedic surgery.

https://pluang.com/en/news-feed/zimmer-biomet-perkenalkan-surgeon-guided-autonomy-kategori-baru-bedah-cerdas
Zimmer Biomet introduced "Surgeon-Guided Autonomy," a new technology framework aimed at enhancing orthopedic surgery by automating cognitive and physical tasks while keeping surgeons in control. This system, part of the Predict, Perform, Recover loop, learns from each case to improve outcomes and reduce surgeon burden. The company's stock, ZBH, is trading at USD 106.85 with a market cap of $20.22 billion.

Enovis (ENOV) Shares Just Moved, So What Is Catching Attention?

https://simplywall.st/stocks/us/healthcare/nyse-enov/enovis/news/enovis-enov-shares-just-moved-so-what-is-catching-attention
Enovis (ENOV) recently reported strong Q3 2026 results, moving from a significant loss to a small profit and announcing a US$200 million share repurchase program. This news has led to a sharp increase in share price, with a 1-day return of 17.2%. Despite recent gains, the company's long-term shareholder returns remain challenging, indicating a mixed picture for investors.

Zimmer Biomet unveils surgeon-guided autonomy concept for OR tech

https://www.streetinsider.com/Corporate+News/Zimmer+Biomet+unveils+surgeon-guided+autonomy+concept+for+OR+tech/27303941.html
Zimmer Biomet Holdings, Inc. introduced "Surgeon-Guided Autonomy," a new technology framework aiming to connect surgical planning, execution, and recovery through intelligent systems. This concept, unveiled at the American Association of Hip and Knee Surgeons Annual Meeting, emphasizes surgeon control while utilizing existing Zimmer Biomet products as building blocks. The company also launched an awareness campaign called "Surgeon-Guided AutonoMe" to highlight its surgeon-centric approach.

Envista (NVST) Stock Could Be Reasonable Given Its Cash Flow Upside

https://simplywall.st/stocks/us/healthcare/nyse-nvst/envista-holdings/news/envista-nvst-stock-could-be-reasonable-given-its-cash-flow-u
Envista Holdings' stock, despite a 41.8% decline over five years, appears reasonable based on its potential cash flow upside. A Discounted Cash Flow (DCF) model suggests an intrinsic value substantially above its current share price of $24.96, supported by expected free cash flow growth into the low to mid-$300 million range over the next few years. While some analysts see the company as undervalued due to its shift towards software and AI tools, others are concerned about potential price cuts in China affecting earnings.

Shoulder Innovations Q3FY26 Results: Revenue up 38% to $16.2 million

https://scanx.trade/stock-market-news/companies/shoulder-innovations-q3fy26-results-revenue-up-38-16-2-million/55472184
Shoulder Innovations reported a significant 38% year-over-year increase in net revenue to $16.2 million for Q3FY26, driven by a 34% rise in implant volumes and higher average selling prices. The company also improved its gross margin to 78.5% and narrowed its net loss, leading to a raised full-year FY26 revenue guidance of $68-$70 million. Strategic product launches and advancements in its robotics platform are key to its continued growth and long-term margin expansion.
Advertisement

Gross margin reaches 78.5% as Shoulder Innovations (SI) grows Q3 revenue.

https://www.stocktitan.net/sec-filings/SI/10-q-shoulder-innovations-inc-quarterly-earnings-report-bf48c431b3bd.html
Shoulder Innovations (SI) reported a 37.7% increase in third-quarter revenue to $16.191 million, up from $11.756 million a year earlier, with gross margin improving to 78.5% from 76.2%. Despite narrowing its net loss to $7.048 million from $8.729 million, the company saw its nine-month operating loss widen to $26.609 million due to increased operating expenses. SI is focusing on continued growth through product development, expansion into outpatient settings, and strategic investments in its ecosystem, including a new robotics platform.

UBS maintains Zimmer Biomet Holdings at Buy, raises price target to $130 from $120

https://www.tradingview.com/news/tradingview:f60552347955d:0-ubs-maintains-zimmer-biomet-holdings-at-buy-raises-price-target-to-130-from-120/
UBS has maintained its "Buy" rating for Zimmer Biomet Holdings (ZBH) and increased its price target from $120 to $130, representing an 8.3% increase. This new price target suggests a 21.7% upside from the stock's closing price of $106.85 on November 5th. Other analysts have recently issued ratings and price targets for ZBH ranging from $107 to $125.

RBC Capital maintains Zimmer Biomet Holdings at Outperform, raises price target to $125 from $110

https://www.tradingview.com/news/tradingview:cec9321c1005d:0-rbc-capital-maintains-zimmer-biomet-holdings-at-outperform-raises-price-target-to-125-from-110/
RBC Capital has maintained its "Outperform" rating on Zimmer Biomet Holdings (ZBH) and increased its price target from $110 to $125, representing a 13.6% hike. This new price target suggests a 13.5% upside from the stock's closing price of $110.15 on November 4. Recent analyst actions show a range of price targets for ZBH between $100 and $125 over the last 30 days.

Truist raises Zimmer Biomet stock price target on robotics progress By Investing.com

https://uk.investing.com/news/stock-market-news/truist-raises-zimmer-biomet-stock-price-target-on-robotics-progress-93CH-4962340
Truist Securities has increased its price target for Zimmer Biomet Holdings Inc. (NYSE:ZBH) to $114 from $106, maintaining a Hold rating due to the company's robotics advancements and strong third-quarter organic revenue growth. Despite operational earnings per share falling below estimates, the company's stock surged 13% over the past week and is considered undervalued according to InvestingPro analysis. Zimmer Biomet also accelerated the launch of its fully-autonomous Monogram platform and received positive price target adjustments from other analysts like Stifel, Jefferies, and BMO Capital following its strong Q3 performance.

Earnings call transcript: Zimmer Biomet tops Q3 2026 estimates, shares jump

https://www.investing.com/news/transcripts/earnings-call-transcript-zimmer-biomet-tops-q3-2026-estimates-shares-jump-93CH-5000451
Zimmer Biomet Holdings exceeded Wall Street's third-quarter 2026 expectations with adjusted earnings of $1.90 per share and revenue of $2.06 billion, prompting a 15.49% jump in its stock. The orthopedic-device maker also raised its full-year outlook, citing strong growth in hips, sports medicine, and technology, despite continued weakness in knees and headwinds from China. Management expressed confidence in its diversified portfolio and the upcoming launch of its Monogram robotics platform to drive future growth.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement